QUELICINTM (Succinylcholine Chloride Injection, USP)

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

SUCCINYLCHOLINE CHLORIDE (UNII: I9L0DDD30I) (SUCCINYLCHOLINE - UNII:J2R869A8YF)

可用日期:

Hospira, Inc.

给药途径:

INTRAMUSCULAR

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see WARNINGS ). The risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. The risk is dependent on the extent and location of the injury. The precise time of onset and the duration of the risk period are not known.

產品總結:

QUELICINTM (Succinylcholine Chloride Injection, USP) is supplied as a clear, colorless solution in the following concentrations and packages: Refrigeration of the undiluted agent will assure full potency until expiration date. All units carry a date of expiration. Store in refrigerator 2° to 8°C (36° to 46°F). The multi-dose vials are stable for up to 14 days at room temperature without significant loss of potency. Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Novaplus is a registered trademark of Vizient, Inc. LAB-1247-4.0 Revised: 02/2019

授权状态:

New Drug Application

产品特点

QUELICIN- SUCCINYLCHOLINE CHLORIDE INJECTION, SOLUTION
HOSPIRA, INC.
----------
QUELICIN
(SUCCINYLCHOLINE CHLORIDE INJECTION, USP)
A short-acting depolarizing skeletal muscle relaxant.
WARNING
RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS
There have been rare reports of acute rhabdomyolysis with hyperkalemia
followed by ventricular
dysrhythmias, cardiac arrest and death after the administration of
succinylcholine to apparently
healthy pediatric patients who were subsequently found to have
undiagnosed skeletal muscle
myopathy, most frequently Duchenne's muscular dystrophy.
This syndrome often presents as peaked T-waves and sudden cardiac
arrest within minutes after
the administration of the drug in healthy appearing pediatric patients
(usually, but not exclusively,
males, and most frequently 8 years of age or younger). There have also
been reports in
adolescents.
Therefore, when a healthy appearing infant or child develops cardiac
arrest soon after
administration of succinylcholine, not felt to be due to inadequate
ventilation, oxygenation or
anesthetic overdose, immediate treatment for hyperkalemia should be
instituted. This should
include administration of intravenous calcium, bicarbonate, and
glucose with insulin, with
hyperventilation. Due to the abrupt onset of this syndrome, routine
resuscitative measures are
likely to be unsuccessful. However, extraordinary and prolonged
resuscitative efforts have
resulted in successful resuscitation in some reported cases. In
addition, in the presence of signs
of malignant hyperthermia, appropriate treatment should be instituted
concurrently.
Since there may be no signs or symptoms to alert the practitioner to
which patients are at risk, it is
recommended that the use of succinylcholine in pediatric patients
should be reserved for
emergency intubation or instances where immediate securing of the
airway is necessary, e.g.,
laryngospasm, difficult airway, full stomach, or for intramuscular use
when a suitable vein is
inaccessible (see PRECAUTIONS: PEDIATRIC USE and